Clinical Discussion on XPOVIO
Loading Map....
XPOVIO (selinexor): Now Approved as Early as First Relapse in Multiple Myeloma
Presented by:
Joseph Mikhael, MD – The Translational Genomics Research Institute (City of Hope)
RSVP:
https://www.karyopharmevents.com/8xS2DA
866-914-9069 VDE_KaryopharmRSVP@veeva.com
Darcy Robson – 602-770-6148 drobson@karyopharm.com
KAR0001354 Please reference this number during registration.